Last month, America was shocked by the case of Turing Pharmaceuticals. Turing, in a blatant show of monopoly muscle, purchased the rights to toxoplasmosis drug Daraprim, only to raise its price from $13.50/pill to $750/pill. For those of you keeping track, that’s a 5,000% price increase. I say “monopoly muscle” because despite the patent for Daraprim technically having expired, no company has yet developed a generic version, according to Techdirt. In other words, Turing has only a functional monopoly on the drug. Perversely, this is good news. The situation would be much, much worse if Daraprim’s patent were still active. And even though Turing’s particular abuse is the one that’s hit the news, the fact is that its abuse is one that goes not only tolerated, but enabled by our dysfunctional patent system on a regular basis.
top of page
Recent PostsSee All
In a comment letter sent to the USPTO, UFPR offers recommendations on how the agency’s work in the next four years can ensure that all Americans experience the benefits of innovation rather than feeli
UFPR Submits Comments to the USPTO on Initiatives for the Robustness and Reliability of Patent Right
United for Patent Reform submitted comments to the United States Patent and Trademark Office (USPTO) on the office’s initiatives to ensure the robustness and reliability of patent rights, offering str
United for Patent Reform submitted comments to the United States Patent and Trademark Office (USPTO) on the patent subject matter eligibility guidance. The letter addresses how the Examination Guidanc
bottom of page